MedPath

Comparing Efficacy and Safety: Vortioxetine vs. Sertraline in Anxiety Disorder Treatment

Phase 4
Conditions
Health Condition 1: F411- Generalized anxiety disorder
Registration Number
CTRI/2024/04/066458
Lead Sponsor
Mitsha Nagpal
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Both male and female patients aged between 18 and 60 years.

2. Those giving written consent/guardians giving written consent (in cases where the patients were too ill to understand the process of informed consent and give an informed choice.)

3. People diagnosed with anxiety disorder as per ICD-10 diagnostic criteria.

4. HAM-A score =18

Exclusion Criteria

1. Systemic or Neurological Disorder affecting Cognition, Behavior or Mental Status.

2. Substance dependence except for Nicotine and Caffeine within the past month of entering the study.

3. Long-standing medical or surgical illnesses.

4. Patients with mental retardation or organic brain disorders.

5. Patients suffering from neurological, metabolic and vascular conditions affecting sexual function.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath